Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey
The results highlight the barriers reported by oncologists/hematologists, pathologists, and surgeons, which may impact the evolving role of NGS in the context of the overall management of cancer patients.
Authors
- Ning Ning (ORCID: https://orcid.org/0000-0002-1568-5386)
- Gboyega Adeboyeje (ORCID: https://orcid.org/0000-0002-1088-751X)
- Allysen Kaminski
- Elizabeth A. Szamreta (ORCID: https://orcid.org/0000-0001-7723-3388)
- Ruchit Shah (ORCID: https://orcid.org/0000-0002-3553-6142)
- Arif Hussain (ORCID: https://orcid.org/0000-0001-8485-4406)
- Jyoti Aggarwal (ORCID: https://orcid.org/0000-0003-2168-3392)
Institutions
- University of Maryland, Baltimore (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Biopharma Co., Ltd. (Japan) (JP)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1080/14796694.2024.2430725
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- European Society for Medical Oncology